

AMERICAN VANGUARD CORP

Form 10-Q

August 06, 2013

[Table of Contents](#)

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 10-Q**

x **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**FOR THE QUARTERLY PERIOD ENDED June 30, 2013**

.. **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**FOR THE TRANSITION PERIOD FROM            TO**

**Commission file number 001-13795**

**AMERICAN VANGUARD CORPORATION**

Edgar Filing: AMERICAN VANGUARD CORP - Form 10-Q

**Delaware**  
(State or other jurisdiction of  
Incorporation or organization)

**95-2588080**  
(I.R.S. Employer  
Identification Number)

**4695 MacArthur Court,**  
**Newport Beach, California**  
(Address of principal executive offices)

**92660**  
(Zip Code)

**(949) 260-1200**

(Registrant's telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of accelerated filer and large accelerated filer in Rule 12b-2 of the Exchange Act. (Check one):

Large Accelerated Filer  Accelerated Filer   
Non-Accelerated Filer  Smaller reporting company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  No

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.

Common Stock, \$.10 Par Value 28,664,462 shares as of July 29, 2013.

**Table of Contents**

**AMERICAN VANGUARD CORPORATION**

**INDEX**

|  | <b>Page Number</b> |
|--|--------------------|
| <b>PART I FINANCIAL INFORMATION</b>  |                    |
| Item 1. Financial Statements (unaudited)   |                    |
| <u>Consolidated Statements of Operations and Comprehensive Income for the three months and six months ended June 30, 2013 and 2012</u> | 3                  |
| <u>Consolidated Balance Sheets as of June 30, 2013 and December 31, 2012</u>   | 4                  |
| <u>Consolidated Statement of Stockholders' Equity for the three months ended March 31, 2013 and June 30, 2013</u>                      | 5                  |
| <u>Consolidated Statements of Cash Flows for the six months ended June 30, 2013 and 2012</u>   | 6                  |
| <u>Notes to Consolidated Financial Statements</u>  | 7                  |
| Item 2. <u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u>                                   | 16                 |
| Item 3. <u>Quantitative and Qualitative Disclosures About Market Risk</u>  | 23                 |
| Item 4. <u>Controls and Procedures</u>   | 23                 |
| <b>PART II OTHER INFORMATION</b>   | 24                 |
| Item 1. <u>Legal Proceedings</u>   | 24                 |
| Item 6. <u>Exhibits</u>  | 25                 |
| <u>SIGNATURES</u>  | 26                 |

**Table of Contents****PART I. FINANCIAL INFORMATION****Item 1. FINANCIAL STATEMENTS****AMERICAN VANGUARD CORPORATION AND SUBSIDIARIES****CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME****(In thousands, except per share data)****(Unaudited)**

|   | <b>For the three months<br/>ended June 30</b> |             | <b>For the six months<br/>ended June 30</b> |             |
|---|---|-------------|---|-------------|
|   | <b>2013</b>                                   | <b>2012</b> | <b>2013</b>                                 | <b>2012</b> |
| Net sales   | \$ 86,761                                     | \$ 84,837   | \$ 208,298                                  | \$ 172,092  |
| Cost of sales   | 44,695  | 46,491      | 112,451                                     | 96,368      |
| Gross profit  | 42,066  | 38,346      | 95,847                                      | 75,724      |
| Operating expenses                                    | 29,169  | 24,104      | 56,798                                      | 47,080      |
| Operating income                                      | 12,897  | 14,242      | 39,049                                      | 28,644      |
| Interest expense                                      | 701   | 721         | 1,248                                       | 1,456       |
| Interest capitalized                                  | (31)  | (112)       | (225)                                       | (148)       |
| Income before provision for income taxes              | 12,227  | 13,633      | 38,026                                      | 27,336      |
| Income tax expense                                    | 3,961   | 4,889       | 12,941                                      | 9,858       |
| Net income  | 8,266   | 8,744       | 25,085                                      | 17,478      |
| Net loss attributable to non-controlling interest     | 120   |             | 216   |             |
| Net income attributable to American Vanguard          | 8,386   | 8,744       | 25,301                                      | 17,478      |
| Change in fair value of interest rate swap            | 174   | 24          | 352   | 46          |
| Foreign currency translation adjustment               | (476)   | (420)       | (69)  | 122         |
| Comprehensive income                                  | \$ 8,084                                      | \$ 8,348    | \$ 25,584                                   | \$ 17,646   |
| Earnings per common share basic                       | \$ .29  | \$ .31      | \$ .89                                      | \$ .63      |
| Earnings per common share assuming dilution           | \$ .29  | \$ .30      | \$ .88                                      | \$ .61      |
| Weighted average shares outstanding basic             | 28,295  | 27,858      | 28,280                                      | 27,740      |
| Weighted average shares outstanding assuming dilution | 28,886  | 28,737      | 28,884                                      | 28,544      |

See notes to consolidated financial statements.

**Table of Contents****AMERICAN VANGUARD CORPORATION AND SUBSIDIARIES****CONSOLIDATED BALANCE SHEETS**

(In thousands, except per share data)

|   | June 30,<br>2013<br>(Unaudited) | Dec. 31,<br>2012<br>(Note) |
|---|---------------------------------|----------------------------|
| <b>ASSETS</b>   |                                 |                            |
| Current assets:   |                                 |                            |
| Cash  | \$ 32,414                       | \$ 38,476                  |
| Receivables:  |                                 |                            |
| Trade, net of allowance for doubtful accounts of \$557 and \$623, respectively  | 67,376                          | 76,073                     |
| Income taxes receivable   | 148                             |                            |
| Other   | 1,414                           | 1,230                      |
|   | 68,938                          | 77,303                     |
| Inventories   | 127,150                         | 87,951                     |
| Prepaid expenses  | 13,411                          | 13,710                     |
| Deferred income tax assets  | 4,877                           | 4,877                      |
| Total current assets  | 246,790                         | 222,317                    |
| Property, plant and equipment, net  | 49,828                          | 45,701                     |
| Intangible assets   | 110,247                         | 113,521                    |
| Other assets  | 30,372                          | 18,351                     |
|   | \$ 437,237                      | \$ 399,890                 |
| <b>LIABILITIES AND STOCKHOLDERS' EQUITY</b>   |                                 |                            |
| Current liabilities:  |                                 |                            |
| Current installments of long-term debt  | \$ 70                           | \$ 16,247                  |
| Current installments of other liabilities   | 1,524                           | 1,839                      |
| Accounts payable  | 23,953                          | 32,838                     |
| Deferred revenue  | 278                             | 20,427                     |
| Accrued program costs   | 88,508                          | 32,335                     |
| Accrued expenses and other payables   | 8,793                           | 8,671                      |
| Income taxes payable  |                                 | 1,313                      |
| Total current liabilities   | 123,126                         | 113,670                    |
| Long-term debt, excluding current installments  | 40,911                          | 36,196                     |
| Other liabilities, excluding current installments   | 4,291                           | 5,425                      |
| Deferred income taxes   | 19,163                          | 19,163                     |
| Total liabilities   | 187,491                         | 174,454                    |
| Commitments and contingent liabilities  |                                 |                            |
| Stockholders' equity:   |                                 |                            |
| Preferred stock, \$.10 par value per share; authorized 400,000 shares; none issued  |                                 |                            |
| Common stock, \$.10 par value per share; authorized 40,000,000 shares; issued 30,972,048 shares at June 30, 2013 and 30,766,730 shares at December 31, 2012 | 3,099                           | 3,077                      |
| Additional paid-in capital  | 56,632                          | 54,323                     |
| Accumulated other comprehensive loss  | (1,479)                         | (1,762)                    |

## Edgar Filing: AMERICAN VANGUARD CORP - Form 10-Q

|  |            |            |
|--|------------|------------|
| Retained earnings  | 196,155    | 174,243    |
|  | 254,407    | 229,881    |
| Less treasury stock, at cost, 2,310,634 shares at both June 30, 2013 and December 31, 2012 | (4,804)    | (4,804)    |
| American Vanguard stockholders' equity   | 249,603    | 225,077    |
| Non-controlling interest   | 143        | 359        |
| Total stockholders' equity   | 249,746    | 225,436    |
|  | \$ 437,237 | \$ 399,890 |

Note: The balance sheet at December 31, 2012 has been derived from the audited financial statements at that date.

See notes to consolidated financial statements.

**Table of Contents****AMERICAN VANGUARD CORPORATION AND SUBSIDIARIES****CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY****(In thousands, except per share data)****For The Three Months Ended March 31, 2013 and June 30, 2013****(Unaudited)**

|  | Common Stock |          |                            | Retained Earnings | Accumulated Other Comprehensive Income (Loss) |        | Treasury Stock |            | Total      |
|--|--------------|----------|----------------------------|-------------------|---|--------|----------------|------------|------------|
|  | Shares       | Amount   | Additional Paid-in Capital |                   | Non-Controlling Interest                      | Shares | Amount         |            |            |
| Balance, December 31, 2012                                   | 30,766,730   | \$ 3,077 | \$ 54,323                  | \$ 174,243        | \$ (1,762)                                    | \$ 359 | 2,310,634      | \$ (4,804) | \$ 225,436 |
| Stocks issued under ESPP                                     | 12,263       | 2        | 376                        |                   |   |        |                |            | 378        |
| Cash dividends on common stock (\$0.07 per share)            |              |          |                            | (1,976)           |   |        |                |            | (1,976)    |
| Foreign currency translation adjustment, net                 |              |          |                            |                   | 407   |        |                |            | 407        |
| Stock based compensation                                     |              |          | 688                        |                   |   |        |                |            | 688        |
| Change in fair value of interest rate swaps                  |              |          |                            |                   | 178   |        |                |            | 178        |
| Stock options exercised and grants of restricted stock units | 144,550      | 15       | 34                         |                   |   |        |                |            | 49         |
| Excess tax benefits from share based payment arrangements    |              |          | 57                         |                   |   |        |                |            | 57         |
| Net income (loss)  |              |          |                            | 16,915            |   | (96)   |                |            | 16,819     |
| Balance, March 31, 2013                                      | 30,923,543   | \$ 3,094 | \$ 55,478                  | \$ 189,182        | \$ (1,177)                                    | 263    | 2,310,634      | \$ (4,804) | \$ 242,036 |
| Cash dividends on common stock (\$0.05 per share)            |              |          |                            | (1,413)           |   |        |                |            | (1,413)    |
| Foreign currency translation adjustment, net                 |              |          |                            |                   | (476)   |        |                |            | (476)      |
| Stock based compensation                                     |              |          | 1,058                      |                   |   |        |                |            | 1,058      |
| Change in fair value of interest rate swaps                  |              |          |                            |                   | 174   |        |                |            | 174        |
| Stock options exercised and grants of restricted stock units | 48,505       | 5        | 96                         |                   |   |        |                |            | 101        |
| Net income (loss)  |              |          |                            | 8,386             |   | (120)  |                |            | 8,266      |
| Balance, June 30, 2013                                       | 30,972,048   | \$ 3,099 | \$ 56,632                  | \$ 196,155        | \$ (1,479)                                    | 143    | 2,310,634      | \$ (4,804) | \$ 249,746 |

**Table of Contents****AMERICAN VANGUARD CORPORATION AND SUBSIDIARIES****CONSOLIDATED STATEMENTS OF CASH FLOWS****(In thousands)****For The Six Months Ended June 30, 2013 and 2012****(Unaudited)**

| <b>Increase (decrease) in cash</b>   | <b>2013</b>      | <b>2012</b>      |
|--|------------------|------------------|
| <b>Cash flows from operating activities:</b>   |                  |                  |
| Net income   | \$ 25,085        | \$ 17,478        |
| <b>Adjustments to reconcile net income to net cash provided by operating activities:</b>           |                  |                  |
| Depreciation and amortization of fixed and intangible assets                                       | 7,461            | 7,046            |
| Amortization of other long term assets   | 1,802            | 1,574            |
| Amortization of discounted liabilities   | 86               | 396              |
| Stock-based compensation   | 1,747            | 1,031            |
| Tax benefit from exercise of stock options   | (57)             | (160)            |
| <b>Changes in assets and liabilities associated with operations:</b>                               |                  |                  |
| Decrease (increase) in net receivables   | 8,513            | (3,862)          |
| Increase in inventories  | (39,199)         | (8,854)          |
| Increase in prepaid expenses and other assets  | (9,837)          | (2,555)          |
| (Decrease) increase in income tax receivable/payable, net  | (1,404)          | 393              |
| (Decrease) increase in accounts payable  | (8,532)          | 668              |
| Decrease in deferred revenue   | (20,149)         | (7,370)          |
| Increase in other payables and accrued expenses  | 54,529           | 30,883           |
| <b>Net cash provided by operating activities</b>   | <b>20,045</b>    | <b>36,668</b>    |
| <b>Cash flows from investing activities:</b>   |                  |                  |
| Capital expenditures   | (8,360)          | (13,061)         |
| Investment   | (3,687)          |                  |
| <b>Net cash used in investing activities</b>   | <b>(12,047)</b>  | <b>(13,061)</b>  |
| <b>Cash flows from financing activities:</b>   |                  |                  |
| Net borrowings under line of credit agreement  | 40,750           |                  |
| Payments on long-term debt   | (46,000)         | (4,000)          |
| Payments on other long-term liabilities  | (1,238)          |                  |
| Tax benefit from exercise of stock options   | 57               | 160              |
| Decrease in other notes payable  | (6,154)          | (6,827)          |
| Payment of cash dividends  | (1,976)          | (1,380)          |
| Proceeds from the issuance of common stock (sale of stock under ESPP and exercise of stock option) | 527              | 1,285            |
| <b>Net cash used in by financing activities</b>  | <b>(14,034)</b>  | <b>(10,762)</b>  |
| <b>Net (decrease) increase in cash</b>   | <b>(6,036)</b>   | <b>12,845</b>    |
| Cash and cash equivalents at beginning of year   | 38,476           | 35,085           |
| Effect of exchange rate changes on cash  | (26)             | 118              |
| <b>Cash and cash equivalents as of June 30</b>   | <b>\$ 32,414</b> | <b>\$ 48,048</b> |



See notes to consolidated financial statements

**Table of Contents****AMERICAN VANGUARD CORPORATION AND SUBSIDIARIES****Notes to Consolidated Financial Statements****(In thousands, except share data)****(Unaudited)**

1. The accompanying unaudited consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation, have been included. Operating results for the six months ended June 30, 2013 are not necessarily indicative of the results that may be expected for the year ending December 31, 2013. For further information, refer to the consolidated financial statements and footnotes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2012.

2. Property, plant and equipment at June 30, 2013 and December 31, 2012 consists of the following:

|  | <b>June 30,<br/>2013</b> | <b>December 31,<br/>2012</b> |
|--|--------------------------|------------------------------|
| Land                                     | \$ 2,458                 | \$ 2,458                     |
| Buildings and improvements               | 12,768                   | 12,537                       |
| Machinery and equipment                  | 91,364                   | 89,089                       |
| Office furniture, fixtures and equipment | 9,108                    | 8,400                        |
| Automotive equipment                     | 278                      | 312                          |
| Construction in progress                 | 8,543                    | 3,363                        |
|  | 124,519                  | 116,159                      |
| Less accumulated depreciation            | (74,691)                 | (70,458)                     |
|  | <b>\$ 49,828</b>         | <b>\$ 45,701</b>             |

3. Inventories are stated at the lower of cost or market. Cost is determined using the first-in, first-out method. The components of inventories consist of the following:

|                   | <b>June 30,<br/>2013</b> | <b>December 31,<br/>2012</b> |
|-------------------|--------------------------|------------------------------|
| Finished products | \$ 115,472               | \$ 74,900                    |
| Raw materials     | 11,678                   | 13,051                       |
|                   | <b>\$ 127,150</b>        | <b>\$ 87,951</b>             |

**Table of Contents**

4. Based on similar economic and operational characteristics, the Company's business is aggregated into one reportable segment. Selective enterprise information is as follows:

|              | Three Months Ended<br>June 30 |           | Six Months Ended<br>June 30 |            |
|--------------|-------------------------------|-----------|-----------------------------|------------|
|              | 2013                          | 2012      | 2013                        | 2012       |
| Net sales:   |                               |           |                             |            |
| Insecticides | \$ 39,218                     | \$ 45,432 | \$ 118,085                  | \$ 101,266 |
| Herbicides   | 24,699                        | 13,656    | 57,685                      | 33,332     |
| Other        | 13,228                        | 16,204    | 16,919                      | 20,583     |
|              | 77,145                        | 75,292    | 192,689                     | 155,181    |
| Non-crop     | 9,616                         | 9,545     | 15,609                      | 16,911     |
|              | \$ 86,761                     | \$ 84,837 | \$ 208,298                  | \$ 172,092 |

|                     | Three Months Ended<br>June 30 |           | Six Months Ended<br>June 30 |            |
|---------------------|-------------------------------|-----------|-----------------------------|------------|
|                     | 2013                          | 2012      | 2013                        | 2012       |
| Net Sales:          |                               |           |                             |            |
| US sales            | \$ 67,837                     | \$ 65,792 | \$ 170,942                  | \$ 135,335 |
| International sales | 18,924                        | 19,045    | 37,356                      | 36,757     |
|                     | \$ 86,761                     | \$ 84,837 | \$ 208,298                  | \$ 172,092 |

5. On June 10, 2013, the Board of Directors declared a cash dividend of \$0.05 per share. At that time, the Board of Directors also resolved to change the frequency of making cash dividends from semi-annual to quarterly payments. The first quarterly dividend was distributed on July 19, 2013 to stockholders of record at the close of business on July 5, 2013. Cash dividends paid July 19, 2013 totaled \$1,413.

On March 11, 2013, the Board of Directors declared a cash dividend of \$0.07 per share. The dividend was distributed on April 19, 2013 to stockholders of record at the close of business on April 5, 2013. Cash dividends paid April 19, 2013 totaled \$1,976.

On March 8, 2012, the Board of Directors declared a cash dividend of \$0.05 per share. The dividend was distributed on April 16, 2012 to stockholders of record at the close of business on April 1, 2012. Cash dividends paid in April 16, 2012 amounted to \$1,380.

6. Financial Accounting Standards Board ( FASB ) Accounting Standards Codification ( ASC ) 260 *Earnings Per Share ( EPS )* requires dual presentation of basic EPS and diluted EPS on the face of all income statements. Basic EPS is computed as net income divided by the weighted average number of shares of common stock outstanding during the period. Diluted EPS reflects potential dilution that could occur if securities or other contracts, which, for the Company, consists of options to purchase shares of the Company's common stock, are exercised.

The components of basic and diluted earnings per share were as follows:

|  | Three Months Ended<br>June 30 |          | Six Months Ended<br>June 30 |           |
|--|-------------------------------|----------|-----------------------------|-----------|
|  | 2013                          | 2012     | 2013                        | 2012      |
| Numerator:                                   |                               |          |                             |           |
| Net income attributable to American Vanguard | \$ 8,386                      | \$ 8,744 | \$ 25,301                   | \$ 17,478 |
| Denominator:                                 |                               |          |                             |           |
| Weighted averages shares outstanding-basic   | 28,295                        | 27,858   | 28,280                      | 27,740    |

Edgar Filing: AMERICAN VANGUARD CORP - Form 10-Q

|   |        |        |        |        |
|---|--------|--------|--------|--------|
| Assumed exercise of stock options and restricted shares-fully diluted | 591    | 879    | 604    | 804    |
|   | 28,886 | 28,737 | 28,884 | 28,544 |

**Table of Contents**

7. Substantially all of the Company's assets are pledged as collateral with its banks.

The Company has various loans in place that together constitute the short-term and long-term loan balances shown in the balance sheet at June 30, 2013 and December 31, 2012. These are summarized in the following table:

| Indebtedness<br>\$000's                                  | June 30, 2013 |            |           | December 31, 2012 |            |           |
|--|---------------|------------|-----------|-------------------|------------|-----------|
|  | Long-term     | Short-term | Total     | Long-term         | Short-term | Total     |
| Term loan  | \$            | \$         | \$        | \$ 36,000         | \$ 10,000  | \$ 46,000 |
| Working capital revolver                                 | 40,750        |            | 40,750    |                   |            |           |
| Notes payable on product acquisitions and asset purchase | 161           | 70         | 231       | 196               | 6,247      | 6,443     |
| Total indebtedness                                       | \$ 40,911     | \$ 70      | \$ 40,981 | \$ 36,196         | \$ 16,247  | \$ 52,443 |

As more fully reported in the Company's Form 8-K (filed with the SEC on June 20, 2013), on June 17, 2013, AMVAC Chemical Corporation (AMVAC), the Company's principal operating subsidiary, as borrower, and affiliates (including the Company), as guarantors and/or borrowers, entered into a Second Amended and Restated Credit Agreement (the New Credit Agreement) with a group of commercial lenders led by Bank of the West (AMVAC's primary bank) as agent, swing line lender and L/C issuer. The new facility also includes both AMVAC CV and AMVAC Netherlands BV (both Dutch subsidiaries) as borrowers. The New Credit Agreement supersedes the Amended and Restated Credit Agreement (First Amendment) dated as of January 10, 2011 and more fully described in the Company's Form 8-K filed on January 13, 2011. The New Credit Agreement is a senior secured lending facility with a five year term and consists of a revolving line of credit of \$200 million and an accordion feature for up to \$100 million. In connection with AMVAC's entering into the New Credit Agreement, all outstanding indebtedness under the First Amendment was rolled over into the New Credit Agreement, and term loans were converted into revolving debt.

At June 30, 2013, the Company had in place one interest rate swap contract with a notional amount of \$40,500 that is accounted for under FASB ASC 815 as a cash flow hedge. The effective portion of the gains or losses on the interest rate swap are reported as a component of other comprehensive income and reclassified into earnings in the same period or periods during which the hedged transactions affect earnings. Losses in other comprehensive income expected to be reclassified to earnings in the coming 12 months are \$616. Amounts recorded in earnings for hedge ineffectiveness for the period ending June 2013 were immaterial.

The following tables illustrate the impact of derivatives on the Company's income statement for the three months and six months ended June 30, 2013.

**The Effect of Derivative Instruments on the Statement of Financial Performance**

**For the Period Ended June 30**

**For the three months ended June 30**

| Derivatives in ASC 815  | Amount of Gain or (Loss) Recognized in OCI on Derivative (Effective Portion) |          | Location of Gain or (Loss) Reclassified from Accumulated OCI into Income (Effective Portion) | Amount of Gain or (Loss) Reclassified from Accumulated OCI into Income (Effective Portion) |          | Location of Gain or (Loss) Recognized in Income on Derivative (Ineffective Portion) | Amount of Gain or (Loss) Recognized in Income on Derivative (Ineffective Portion) |      |
|-------------------------|--|----------|--|--|----------|---|---|------|
|                         | 2013   | 2012     |  | 2013   | 2012     |   | 2013  | 2012 |
| Cash Flow               |  |          |  |  |          |   |   |      |
| Hedging Relationships   |  |          |  |  |          |   |   |      |
| Interest rate contracts | \$ (7)   | \$ (159) | Interest Expense   | \$ (181)   | \$ (183) | Interest Expense  | \$  | \$   |
| Total                   | \$ (7)   | \$ (159) |  | \$ (181)   | \$ (183) |   | \$  | \$   |

Edgar Filing: AMERICAN VANGUARD CORP - Form 10-Q

|  | Location of Gain or (Loss) Recognized in Income on Derivative | Amount of Gain or (Loss) Recognized in Income on Derivative |          |
|--|---|---|----------|
|  |   | 2013  | 2012     |
| <b>Derivatives Not Designated as Hedging Instruments under ASC 815</b> |   |   |          |
| Foreign Exchange contracts   | Other income/(expense)  | \$  | \$ (337) |
| Total  |   | \$  | \$ (337) |

**Table of Contents**

For the six months ended June 30

| Derivatives in ASC 815 Cash Flow | Amount of Gain or (Loss) Recognized in OCI on Derivative (Effective Portion) |          | Location of Gain or (Loss) Reclassified from Accumulated OCI into Income (Effective Portion) | Amount of Gain or (Loss) Recognized from Accumulated OCI into Income (Effective Portion) |          | Location of Gain or (Loss) Recognized in Income on Derivative (Ineffective Portion) | Amount of Gain or (Loss) Recognized in Income on Derivative (Ineffective Portion) |        |
|----------------------------------|--|----------|--|--|----------|---|---|--------|
|                                  | 2013   | 2012     |  | 2013   | 2012     |   | 2013  | 2012   |
| Hedging Relationships            |  |          |  |  |          |   |   |        |
| Interest rate contracts          | \$ (14)  | \$ (322) | Interest Expense   | \$ (366)   | \$ (368) | Interest Expense  | \$ (1)  | \$ (1) |
| Total                            | \$ (14)  | \$ (322) |  | \$ (366)   | \$ (368) |   | \$ (1)  | \$ (1) |

| Derivatives Not Designated as Hedging Instruments under ASC 815 | Location of Gain or (Loss) Recognized in Income on Derivative |  | Amount of Gain or (Loss) Recognized in Income on Derivative |          |
|---|---|--|---|----------|
|   |   |  | 2013  | 2012     |
| Foreign Exchange contracts                                      | Other income/(expense)  |  | \$  | \$ (192) |
| Total   |   |  | \$  | \$ (192) |

The Company has three key covenants to its senior, secured credit facility with its banking syndicate. The covenants are as follows: (1) the Company must maintain its borrowings below a certain consolidated funded debt ratio, (2) the Company has a limitation on its annual spending on the acquisition of fixed asset capital additions, and (3) the Company must maintain a certain consolidated fixed charge coverage ratio. As of June 30, 2013 the Company met all covenants in that credit facility.

At June 30, 2013, based on its performance against the most restrictive covenants listed above, the Company had the capacity to increase its borrowings by up to \$159,250 under the credit facility agreement.

8. Reclassification certain items may have been reclassified (if appropriate), in the prior period consolidated financial statements to conform to the most recent financial statements presented.

9. Total comprehensive income includes, in addition to net income, changes in equity that are excluded from the consolidated statements of operations and are recorded directly into a separate section of stockholders' equity on the consolidated balance sheets.

10. Stock Based Compensation Expense The Company accounts for stock-based awards to employees and directors in accordance with FASB ASC 718, *Share-Based Payment*, which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees and directors, including shares of common stock granted for services, employee stock options, and employee stock purchases related to the Employee Stock Purchase Plan ( employee stock purchases ) based on estimated fair values.

**Table of Contents**

Stock Options During the six months ended June 30, 2013, the Company did not grant any employees options to acquire shares of common stock.

Option activity within each plan is as follows:

|  | Incentive<br>Stock Option<br>Plans | Weighted Average<br>Price Per<br>Share | Exercisable<br>Weighted<br>Average<br>Price<br>Per Share |
|--|------------------------------------|--|--|
| Balance outstanding, December 31, 2012 | 705,345                            | \$ 7.70                                | \$ 7.95  |
| Options granted                        |                                    |  |  |
| Options exercised, \$7.50              | (6,666)                            | 7.50                                   |  |
| Options expired or forfeited           | (6,667)                            | 7.50                                   |  |
| Balance outstanding, March 31, 2013    | 692,012                            | \$ 7.71                                | \$ 7.96  |
| Options granted                        |                                    |  |  |
| Options exercised, \$7.50              | (13,333)                           | 7.50                                   |  |
| Options expired or forfeited           |                                    |  |  |
| Balance outstanding, June 30, 2013     | 678,679                            | \$ 7.71                                | \$ 8.07  |

Information relating to stock options at June 30, 2013 summarized by exercise price is as follows:

| Exercise Price Per Share     | Outstanding Weighted Average Remaining |               |                | Exercisable Weighted Average |                |
|------------------------------|--|---------------|----------------|------------------------------|----------------|
|                              | Shares                                 | Life (Months) | Exercise Price | Shares                       | Exercise Price |
| Incentive Stock Option Plan: |  |               |                |                              |                |
| \$7.50                       | 652,000                                | 85            | \$ 7.50        | 146,000                      | \$ 7.50        |
| \$11.32 \$14.75              | 26,679                                 | 86            | \$ 12.90       | 16,679                       | \$ 13.08       |
|                              | 678,679                                |               | \$ 7.71        | 162,679                      | \$ 8.07        |

The weighted average exercise prices for options granted and exercisable and the weighted average remaining contractual life for options outstanding as of June 30, 2013 was as follows:

|                               | Number<br>of<br>Shares | Weighted<br>Average<br>Exercise<br>Price | Weighted<br>Average<br>Remaining<br>Contractual<br>Life<br>(Months) | Intrinsic<br>Value<br>(thousands) |
|-------------------------------|------------------------|--|---|-----------------------------------|
| <i>As of June 30, 2013:</i>   |                        |  |   |                                   |
| Incentive Stock Option Plans: |                        |  |   |                                   |
| Outstanding                   | 678,679                | \$ 7.71                                  | 85  | \$ 10,633                         |
| Expected to Vest              | 674,823                | \$ 7.71                                  | 85  | \$ 10,573                         |
| Exercisable                   | 162,679                | \$ 8.07                                  | 72  | \$ 2,490                          |

During the six months ended June 30, 2013 and 2012, the Company recognized stock-based compensation expense, excluding expense associated with modifications, related to stock options of \$423 and \$432, respectively.



## Edgar Filing: AMERICAN VANGUARD CORP - Form 10-Q

As of June 30, 2013, the Company had approximately \$400 of unamortized stock-based compensation expenses related to unvested stock options outstanding. This amount will be recognized over the weighted-average period of 0.5 years. This projected expense will change if any stock options are granted or cancelled prior to the respective reporting periods or if there are any changes required to be made for estimated forfeitures.

**Table of Contents**

Restricted Shares A status summary of non-vested shares as of and for the six months ended June 30, 2013 is presented below:

|                                       | Number<br>of<br>Shares | Weighted<br>Average<br>Grant-<br>Date<br>Fair Value |
|---------------------------------------|------------------------|---|
| Nonvested shares at December 31, 2012 | 245,817                | \$ 20.23  |
| Granted                               | 145,884                | \$ 31.27  |
| Vested                                |                        | \$  |
| Forfeited                             | (8,000)                | \$ 22.17  |
| Nonvested shares at March 31, 2013    | 383,701                | \$ 24.39  |
| Granted                               | 8,230                  | \$ 30.37  |
| Vested                                | (8,230)                | \$ 30.37  |
| Forfeited                             |                        | \$  |
| Nonvested shares at June 30, 2013     | 383,701                | \$ 24.39  |

Restricted stock grants During the six months ended June 30, 2013, the Company granted a total of 154,114 shares of common stock. Of these, 3,000 shares will vest one-third each year on the anniversaries of the employee's employment date, 8,230 shares vests immediately, and the balance will cliff vest after three years of service. The shares granted in 2013 were average fair valued at \$31.22 per share. The fair value was determined by using the publicly traded share price as of the date of grant. The Company is recognizing as expense the value of restricted shares over the required service period.

During the six months ended June 30, 2012, the Company granted a total of 207,184 of common stock. Of these, 12,204 shares vest immediately and the balance will cliff vest after three years of service. The shares granted in 2012 were average fair valued at \$20.45 per share. The fair value was determined by using the publicly traded share price as of the date of grant. The Company is recognizing as expense the value of restricted shares over the required service period. During the six months ended June 30, 2012, there were 82,640 restricted shares that vested, which had an average grant-date value of \$11.73 per share and an average vest-date value of \$17.58 per share. During the six months ended June 30, 2012, there were 1,367 restricted shares that were forfeited, which had an average grant date value of \$20.47 per share.

During the six months ended June 30, 2013 and 2012, the Company recognized stock-based compensation expense related to restricted shares of \$1,297 and \$599, respectively.

As of June 30, 2013, the Company had approximately \$7,132 of unamortized stock-based compensation expenses related to unvested restricted shares. This amount will be recognized over the weighted-average period of 2.3 years. This projected expense will change if any restricted shares are granted or cancelled prior to the respective reporting periods or if there are any changes required to be made for estimated forfeitures.

**Table of Contents**

Performance Based Shares A status summary of non-vested performance based shares as of and for the six months ended June 30, 2013 is presented below:

|                                    | Number<br>of<br>Shares | Weighted<br>Average<br>Grant-<br>Date<br>Fair Value |
|------------------------------------|------------------------|---|
| Nonvested shares at March 31, 2013 |                        | \$  |
| Granted                            | 26,942                 | \$ 30.13  |
| Vested                             |                        | \$  |
| Forfeited                          |                        | \$  |
| Nonvested shares at June 30, 2013  | 26,942                 | \$ 30.13  |

Performance Based Shares During the six months ended June 30, 2013, the Company granted a total of 26,942 performance based shares that will cliff vest after three years of service. 80% of these performance based shares are based upon net income and net sales for the period commencing April 1, 2013 and ending December 31, 2015; the remaining 20% of performance based shares are based upon AVD stock price appreciation over the course of the period commencing June 6, 2013 and ending on December 31, 2015. Both parts of these awards vest in three years, but are subject to reduction to a minimum (or even zero) for meeting less than the targeted performance and to increase to a maximum of 200% for meeting in excess of the targeted performance.

The performance based shares related to net income and net sales were average fair valued at \$30.13 per share. The fair value was determined by using the publicly traded share price as of the date of grant. The performance based shares related to AVD stock price were average fair valued at \$15.31 per share. The fair value was determined by using the Monte Carlo valuation method. The Company is recognizing as expense the value of these shares over the required service period of three years.

During the six months ended June 30, 2013, the Company recognized stock-based compensation expense related to performance based shares of \$26. There were no performance based shares issued by the Company prior to those issued during the quarter ended June 30, 2013.

As of June 30, 2013, the Company had approximately \$716 of unamortized stock-based compensation expenses related to unvested performance based shares. This amount will be recognized over the weighted-average period of 2.9 years. This projected expense will change if any performance based shares are granted or cancelled prior to the respective reporting periods or if there are any changes required to be made for estimated forfeitures.

11. Legal Proceedings Summarized below are litigation matters in which there has been material activity or developments during the three month period ended June 30, 2013.

**A. DBCP Cases Delaware**

On or about July 21, 2011, an action encaptioned, *Blanco v. AMVAC Chemical Corporation et al.*, was filed with the Superior Court of the State of Delaware in and for New Castle County (No. N11C-07-149 JOH) on behalf of an individual plaintiff, residing in Costa Rica, against several defendants, including, among others, AMVAC, The Dow Chemical Company, Occidental Chemical Corporation, and Dole Food Company. In the action, plaintiff claims personal injury (sterility) arising from the alleged exposure to DBCP between 1979 and 1980 while working as a contract laborer in a banana plantation in Costa Rica. Defendant Dow filed a motion to dismiss the action as being barred under the applicable statute of limitations, as this same plaintiff filed the same claim in Florida in 1995 and subsequently withdrew the matter. Plaintiff contends that the statute of limitations was tolled by a prior motion for class certification, which was denied. AMVAC contends that the plaintiff could not have been exposed to any DBCP supplied by AMVAC in Costa Rica. On August 8, 2012, the court denied Dow's motion to dismiss based upon applicable statutes of limitation. In response to that denial, on

**Table of Contents**

August 20, 2012, defendants filed a motion for interlocutory appeal and, on September 18, 2012, the Delaware Supreme Court granted interlocutory appeal on the question of whether the State of Delaware will recognize cross jurisdictional tolling (that is, whether it is proper for a Delaware court to follow the class action tolling of another jurisdiction, in this case, Texas, rather than its own two year statute of limitations). Pending the ruling on appeal, the *Blanco* matter was stayed. A similar case (referred to as *Chaverri* in the Company's Form 10-K for the period ended December 31, 2012) involving claims for personal injury allegedly arising from exposure to DBCP on behalf of 235 banana workers from Costa Rica, Ecuador and Panama was also stayed pending the ruling. The Delaware Supreme Court heard oral argument on April 10, 2013 and on June 10, 2013, denied the appeal and upheld the lower court ruling in *Blanco*, holding that it was proper to extend the class action tolling exception to cross-jurisdictional class action cases. With that ruling, both the *Blanco* and *Chaverri* matters remain pending. AMVAC intends to defend both of these matters vigorously and, at this early stage of litigation, does not believe that a loss is either probable or reasonably estimable and has not set up a loss contingency for either matter.

12. Recently Issued Accounting Guidance In February 2013, The Financial Accounting Standards Board ( FASB ) issued Accounting Standards Update ( ASU ) 2013-02, *Comprehensive Income (Topic 220): Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income*, establishes new requirements for disclosing reclassifications of items out of accumulated other comprehensive income (OCI). Specifically, (1) disclosure is required of the changes in components of accumulated OCI, (2) disclosure is required of the effects on individual line items in net income for each item of accumulated OCI that is reclassified in its entirety to net income, and (3) cross references are required to other disclosures that provide additional details for OCI items that are not reclassified in their entirety to net income. The requirements of ASU 2013-02 apply to all entities (i.e., both public and nonpublic) that report items of OCI in any period presented. ASU 2013-02 is effective prospectively for reporting periods beginning after December 15, 2012.

In October 2012, FASB issued ASU No. 2012-04, Technical Corrections and Improvements. This update primarily makes amendments to various Codifications to (1) conform the format and writing style of certain guidance carried forward without modification from pre-Codification pronouncements, (2) to correct references and provide clarification through updated language, and (3) to relocate guidance within the Codification to a more appropriate location. In addition, ASU No. 2012-4 conforms the use of the term *fair value* throughout the Codification to reflect fully the measurement and disclosure requirements of FASB ASC Topic 820, *Fair Value Measurement and Disclosures* (e.g. to replace the terms market value and mark-to-market with fair value and subsequently measure at fair value, respectively). The majority of the amendments do not change the accounting practice. However, where applicable, the Company will apply the updates.

13. Fair Value of Financial Instruments The carrying values of cash, receivables and accounts payable approximate their fair values because of the short maturity of these instruments. The fair value of the Company's long-term debt and note payable to the bank is estimated based on the quoted market prices for the same or similar issues or on the current rates offered to the Company for debt of the same remaining maturities. Such fair value approximates the respective carrying values of the Company's long-term debt and note payable to the bank.

The Company's cash flow hedge related to a variable debt instrument and outstanding foreign currency derivatives used to hedge foreign currency balances are measured at fair value on a recurring basis, and the balances as of June 30, 2013 and December 31, 2012 (which are included in other assets, net and accrued and other liabilities in the consolidated balance sheets) were as follows:

|  | Fair Value Measurements<br>Using Input Type |          |         |
|--|---|----------|---------|
|  | Level 1                                     | Level 2  | Level 3 |
| As of June 30, 2013:                               |   |          |         |
| Liability:   |   |          |         |
| Foreign currency derivative financial instrument   | \$  | \$       | \$      |
| Interest rate derivative financial instruments (1) | \$  | \$ 848   | \$      |
| As of December 31, 2012:                           |   |          |         |
| Liability:   |   |          |         |
| Foreign currency derivative financial instrument   | \$  | \$ 160   | \$      |
| Interest rate derivative financial instruments (1) | \$  | \$ 1,201 | \$      |

(1) Includes accrued interest expense

**Table of Contents**

The valuation techniques used to measure the fair value of the derivative financial instruments above in which the counterparties have high credit ratings, were derived from pricing models, such as discounted cash flow techniques, with all significant inputs derived from or corroborated by observable market data. The Company's discounted cash flow techniques use observable market inputs, such as LIBOR-based yield curves and foreign currency forward rates.

## 14. Accumulated Other Comprehensive Income

The following table lists the beginning balance, annual activity and ending balance of each component of accumulated other comprehensive income:

|  | <b>Interest<br/>Rate<br/>Swap</b> | <b>FX<br/>Translation</b> | <b>Total</b> |
|--|-----------------------------------|---------------------------|--------------|
| Balance, December 31, 2012                 | \$ (728)                          | \$ (1,034)                | \$ (1,762)   |
| Current period, other comprehensive income | 178                               | 407                       | 585          |
| Balance, March 31, 2013                    | \$ (550)                          | \$ (627)                  | \$ (1,177)   |
| Current period, other comprehensive income | 174                               | (476)                     | (302)        |
| Balance, June 30, 2013                     | \$ (376)                          | \$ (1,103)                | \$ (1,479)   |

**Table of Contents****Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS**  
(Numbers in thousands)**FORWARD-LOOKING STATEMENTS/RISK FACTORS:**

The Company, from time-to-time, may discuss forward-looking statements including assumptions concerning the Company's operations, future results and prospects. These forward-looking statements are based on current expectations and are subject to a number of risks, uncertainties and other factors. In connection with the Private Securities Litigation Reform Act of 1995, the Company provides the following cautionary statements identifying important factors which, among other things, could cause the actual results and events to differ materially from those set forth in or implied by the forward-looking statements and related assumptions contained in the entire Report. Such factors include, but are not limited to: product demand and market acceptance risks; the effect of economic conditions; weather conditions; changes in regulatory policy; the impact of competitive products and pricing; changes in foreign exchange rates; product development and commercialization difficulties; capacity and supply constraints or difficulties; availability of capital resources; general business regulations, including taxes and other risks as detailed from time-to-time in the Company's reports and filings filed with the U.S. Securities and Exchange Commission (the "SEC"). It is not possible to foresee or identify all such factors. For more detailed information, refer to Item 1A., Risk factors and Item 7A., Quantitative and Qualitative Disclosures about Market Risk, in the Company's Annual Report on Form 10-K for the year ended December 31, 2012.

**RESULTS OF OPERATIONS****Quarter Ended June 30:**

|                          | 2013             | 2012             | Change            |
|--------------------------|------------------|------------------|-------------------|
| <b>Net sales:</b>        |                  |                  |                   |
| Insecticides             | \$ 39,218        | \$ 45,432        | \$ (6,214)        |
| Herbicides               | 24,699           | 13,656           | 11,043            |
| Other                    | 13,228           | 16,204           | (2,976)           |
| <b>Total Crop</b>        | <b>77,145</b>    | <b>75,292</b>    | <b>1,853</b>      |
| Non-crop                 | 9,616            | 9,545            | 71                |
|                          | <b>\$ 86,761</b> | <b>\$ 84,837</b> | <b>\$ 1,924</b>   |
| <b>Cost of sales:</b>    |                  |                  |                   |
| Insecticides             | \$ 21,386        | \$ 24,697        | \$ (3,311)        |
| Herbicides               | 11,958           | 8,988            | 2,970             |
| Other                    | 6,910            | 8,045            | (1,135)           |
| <b>Total crop</b>        | <b>40,254</b>    | <b>41,730</b>    | <b>(1,476)</b>    |
| Non-crop                 | 4,441            | 4,761            | (320)             |
|                          | <b>\$ 44,695</b> | <b>\$ 46,491</b> | <b>\$ (1,796)</b> |
| <b>Gross margin:</b>     |                  |                  |                   |
| Insecticides             | \$ 17,832        | \$ 20,735        | \$ (2,903)        |
| Herbicides               | 12,741           | 4,668            | 8,073             |
| Other                    | 6,318            | 8,159            | (1,841)           |
| <b>Gross margin crop</b> | <b>36,891</b>    | <b>33,562</b>    | <b>3,329</b>      |
| Gross margin non-crop    | 5,175            | 4,784            | 391               |
|                          | <b>\$ 42,066</b> | <b>\$ 38,346</b> | <b>\$ 3,720</b>   |
| Gross margin crop        | 48%              | 45%              |                   |
| Gross margin non-crop    | 55%              | 50%              |                   |

## Edgar Filing: AMERICAN VANGUARD CORP - Form 10-Q

Total gross margin 49%                      45%

|                     | 2013      | 2012      | Change   |
|---------------------|-----------|-----------|----------|
| Net sales:          |           |           |          |
| US sales            | \$ 67,837 | \$ 65,792 | \$ 2,045 |
| International sales | 18,924    | 19,045    | (121)    |
|                     | \$ 86,761 | \$ 84,837 | \$ 1,924 |

Financial performance for the quarter ended June 30, 2013 included net sales that were up 2.3% to \$87,761 compared to \$84,837 for the second quarter of 2012. This revenue performance is now the highest second quarter sales performance recorded by the Company. Our gross profit performance improved and ended at \$42,066 or 48% of sales as compared \$38,346 or 45% of sales last year. Our operating costs for the period increased as a percentage of sales primarily because these are substantially fixed costs which have been put in place to support long-term development and growth of the business, and also included some significant one-time costs as more fully described in our discussion of operating expenses. Our tax rate improved and our net income attributed to American Vanguard, which was down 4% from the prior year, was nevertheless at our target rate of 10% of net sales. Net sales for our crop business were up by approximately 2.5%, while net sales for non-crop products were up by about 1% for the comparable period of the prior year. A more detailed discussion of general market conditions and sales performance by category of products appears below.

Second quarter financial performance was significantly influenced by weather in the United States. Continuous rainfall in the Midwest created considerable difficulties in the planting of the 2013 corn crop. In some areas of northern Iowa and southern Minnesota, field flooding made it impossible to get the crop planted. In other areas of the Corn Belt, persistent rainy weather minimized the days available to plant, causing many growers to bypass some crop defense applications at the time of planting, in order to focus exclusively on getting their seed into the ground. While wet conditions did not adversely affect the sales of either our corn insecticides or corn herbicide for the reporting period, they did affect the use of these products, leaving higher than normal stocks in customers' inventories. Similar conditions in the Southern U.S. had the effect of shortening the necessary growing season, prompted some cotton growers to switch their acres to soybeans and, in turn, led to a drop in the sale of our cotton products. In addition to persistent wet conditions, our sales performance was affected by a drop in peanut acres.



**Table of Contents**

Net sales of our total insecticide group were down about 13%, at \$39,218 as compared to \$45,432 during the second quarter of 2012. Net sales of our granular soil insecticides ( GSIs ) were up approximately 1% over that of the comparable quarter in 2012, led by our four products for corn (Aztec, SmartChoice, Counter and Force) offset by a more than 50% decline in Thimet sales attributable to fewer peanut acres being planted in 2013. Our non-GSI insecticides posted lower sales during the second quarter (down about 40%) primarily due to lighter purchases of our cotton product Bidrin a direct consequence of the wet weather induced shift from cotton to soybeans plantings as discussed above.

Within the group of herbicides/fungicides/fumigants, net sales for the second quarter of 2013 increased by approximately 81% to \$24,699 from \$13,656 in the comparable period of 2012. Net sales of our herbicide products nearly tripled, due primarily to strong sales of our post-emergent corn herbicide, Impact. We benefitted from our continuing co-marketing agreement with Monsanto and the greater supply availability that we secured this year. Our fumigant sales were lower as a result of some localized irrigation restrictions in California. Our fungicide PCNB continued to recapture business, roughly doubling its prior year quarterly sales level.

Within the group of other products (which includes plant growth regulators, molluscicides and tolling activity), our net sales dropped by about 20% as compared to those in the second quarter of 2012. This decrease was due largely to a decline in sales of our cotton harvest defoliant, Folex, as lower cotton plantings caused a slowdown in purchases during the spring before subsequent use of the product in the autumn.

Our non-crop sales ended the second quarter of 2013 at \$9,616 as compared to \$9,545 for the same period of the prior year. This slight increase resulted from sales of our mosquito adulticide Dibrom<sup>®</sup>, which was up 25% as a result of wet conditions discussed above and in preparation for the potential of autumn Gulf Coast hurricane activity, offset by declines in tolling revenues.

Our cost of sales for the second quarter of 2013 was \$44,695 or 51% of net sales. This compared to \$46,491 or 55% of net sales for 2012. The Company aggregates a number of key variable, semi-variable and fixed cost components within reported cost of sales. The two major components are raw materials (including sub contract costs) and factory operating costs. As a result of a change in the sales mix and volume, our absolute expense for raw materials reduced by 4% in the quarter ended June 30, 2013, as compared to the same period of the prior year. Within this change, our actual purchasing cost for raw material increased by 0.8%. Furthermore, with increased demand for plant capacity relating to the production of our own products, we continued to reduce volume manufacturing activity for third parties. Typically, these activities included some raw materials supplied by the customer and, as such, tend to have lower raw material cost (as a percentage of sales) reported by the Company. Our factory operating costs (which include fixed and semi-variable costs) increased by 22%, supporting the forecasted increase in sales revenue for the second quarter and for the balance of the year. Some production ended in inventory because of the unexpected prolonged adverse weather conditions in our key markets. Costs also increased by approximately 3% for inflation. The changes in selling price, volume, product mix and cost of sales resulted overall in a 4% improvement in gross margin to 49% in 2013 as compared to 45% for the same period of the prior year.

It should be noted that, when making comparisons with other companies' financial statements, the Company reports distribution costs in operating expenses and not as part of cost of sales.

Operating expenses increased by \$5,065 to \$29,169 for the three months ended June 30, 2013 as compared to the same period in 2012. The differences in operating expenses by department are as follows:

|  | 2013      | 2012      | Change   |
|--|-----------|-----------|----------|
| Selling                                      | \$ 8,451  | \$ 6,401  | \$ 2,050 |
| General and administrative                   | 9,958     | 7,776     | 2,182    |
| Research, product development and regulatory | 5,068     | 4,967     | 101      |
| Freight, delivery and warehousing            | 5,692     | 4,960     | 732      |
|  | \$ 29,169 | \$ 24,104 | \$ 5,065 |

**Table of Contents**

Selling expenses increased by approximately 32% over the same quarter of the prior year. The main drivers for increased overall expenses were costs associated with servicing our growing business including an expanded sales force, field stewardship activities and advertising and promotion expenses.

General and administrative expenses increased by 28% to \$9,958 as compared to \$7,776 for the same period of the prior year. The main drivers for the increase are primarily related to higher legal costs associated with a data compensation matter, which concluded in July, other outside consulting services associated with business development including our international structure and extra personnel costs in support of our expanding business.

Research, product development costs and regulatory expenses increased by about 2% over the comparable three month period of the prior year, driven by timing and mix on external regulatory projects.

Freight, delivery and warehousing costs increased by about 15%, which was driven primarily by mix of products and markets. We continue to focus on managing logistics expenses throughout our supply chain. As a percentage of sales, freight ended at 6.6% of sales for the three months ended June 30, 2013 as compare to 5.8% for the same period of the prior year.

Interest costs net of capitalized interest, were \$670 in the three months ended June 30, 2013, as compared to \$609 in the same period of 2012. Interest costs are summarized in the following table:

**Average Indebtedness and Interest expense**

|  | Average Debt | Q2 2013 Interest Expense | Interest Rate | Average Debt | Q2 2012 Interest Expense | Interest Rate |
|--|--------------|--------------------------|---------------|--------------|--------------------------|---------------|
| Term loan                                  | \$ 42,054    | \$ 407                   | 3.9%          | \$ 51,956    | \$ 477                   | 3.7%          |
| Working capital revolver                   | 33,725       | 189                      | 2.2%          |              |                          |               |
| Average                                    | 75,779       | 596                      | 3.1%          | 51,956       | 477                      | 3.7%          |
| Other notes payable                        | 242          | 2                        | 3.3%          | 6,223        | 54                       | 12.8%         |
| Capitalized interest                       |              | (31)                     |               |              | (112)                    |               |
| Amortization of deferred loan fees         |              | 38                       |               |              | 32                       |               |
| Amortization of other deferred liabilities |              | 56                       |               |              | 143                      |               |
| Other interest expense                     |              | 9                        |               |              | 15                       |               |
| Adjusted average indebtedness              | \$ 76,021    | \$ 670                   | 3.5%          | \$ 58,179    | \$ 609                   | 4.2%          |

The Company's average overall debt for the three months ended June 30, 2013 was \$76,021 as compared to \$58,179 for the three months ended June 30, 2012. Furthermore, during the three months to June 30, 2013, we incurred non-cash costs related to amortization of discounting of deferred payments and other interest expense in the amount of \$74 as compared to \$132 for the same period of the prior year. As can be seen from the table above, the effective rate on our bank borrowings was 3.1% for the period to June 30, 2013 as compared to 3.7% for the same period of the prior year. Our overall effective interest rate was 3.5% for the three months ended June 30, 2013 as compared to 4.2% at June 30, 2012.

Income tax expense has decreased by \$928 to end at \$3,961 for the three months ended June 30, 2013 as compared to \$4,889 for the comparable period in 2012. The effective tax rate for the quarter was 32.40% as compared to 35.86% in the same period of the prior year. The reduction in the rate is primarily driven by the increased benefit from domestic production activities, Alabama income tax capital credit, and higher foreign income.

Our overall net income attributed to American Vanguard for the three months ended June 30, 2013 was \$8,386 or \$0.29 per share (diluted) as compared to \$8,744 or \$0.30 per share (diluted) in the same quarter of 2012.



**Table of Contents****Six Months Ended June 30:**

|                              | 2013              | 2012              | Change           |
|------------------------------|-------------------|-------------------|------------------|
| <b>Net sales:</b>            |                   |                   |                  |
| Insecticides                 | \$ 118,085        | \$ 101,266        | \$ 16,819        |
| Herbicides                   | 57,685            | 33,332            | 24,353           |
| Other                        | 16,919            | 20,583            | (3,664)          |
| <b>Total crop</b>            | <b>192,689</b>    | <b>155,181</b>    | <b>37,508</b>    |
| <b>Non-crop</b>              | <b>15,609</b>     | <b>16,911</b>     | <b>(1,302)</b>   |
|                              | <b>\$ 208,298</b> | <b>\$ 172,092</b> | <b>\$ 36,206</b> |
| <b>Cost of goods sold:</b>   |                   |                   |                  |
| Insecticides                 | \$ 65,677         | \$ 52,760         | \$ 12,917        |
| Herbicides                   | 29,948            | 21,774            | 8,174            |
| Other                        | 8,300             | 13,082            | (4,782)          |
| <b>Total crop</b>            | <b>103,925</b>    | <b>87,616</b>     | <b>16,309</b>    |
| <b>Non-crop</b>              | <b>8,526</b>      | <b>8,752</b>      | <b>(226)</b>     |
|                              | <b>\$ 112,451</b> | <b>\$ 96,368</b>  | <b>\$ 16,083</b> |
| <b>Gross margin:</b>         |                   |                   |                  |
| Insecticides                 | \$ 52,408         | \$ 48,506         | \$ 3,902         |
| Herbicides                   | 27,737            | 11,558            | 16,179           |
| Other                        | 8,619             | 7,501             | 1,118            |
| <b>Gross margin crop</b>     | <b>88,764</b>     | <b>67,565</b>     | <b>21,199</b>    |
| <b>Gross margin non-crop</b> | <b>7,083</b>      | <b>8,159</b>      | <b>(1,076)</b>   |
|                              | <b>\$ 95,847</b>  | <b>\$ 75,724</b>  | <b>\$ 20,123</b> |
| <b>Gross margin crop</b>     | <b>46%</b>        | <b>44%</b>        |                  |
| <b>Gross margin non-crop</b> | <b>46%</b>        | <b>48%</b>        |                  |
| <b>Total gross margin</b>    | <b>46%</b>        | <b>44%</b>        |                  |
|                              | 2013              | 2012              | Change           |
| <b>Net sales:</b>            |                   |                   |                  |
| US sales                     | \$ 170,942        | \$ 135,335        | \$ 35,607        |
| International sales          | 37,356            | 36,757            | 599              |
|                              | <b>\$ 208,298</b> | <b>\$ 172,092</b> | <b>\$ 36,206</b> |

Overall financial performance including net sales and net income for the six month period ended June 30, 2013 showed considerable improvement as compared to the same period in 2012. Net sales for the period were up approximately 21% to \$208,298 compared to \$172,092 for the first half of 2012. Our gross profit performance improved to \$95,847 or 46% of net sales, as compared to \$75,724 or 44% of net sales. Our operating expenses remained flat as a percentage of net sales at 27%, despite our continuing investment in resources aimed at growing, developing and maintaining our business for the long-term. Our tax rate improved from 36% of taxable income to 34%. Further, net income attributed to American Vanguard was up approximately 45% to \$25,301 (or 12.1% of net sales) as compared to \$17,478 (or 10.2% of net sales) for the same period in 2012. Net sales for our crop business were up by approximately 24%, while net sales for non-crop products were down by about 8% for the comparable period of the prior year. A more detailed discussion of general market conditions and sales performance by category of products appears below.

## Edgar Filing: AMERICAN VANGUARD CORP - Form 10-Q

Over the course of the first half of 2013, the Company experienced strong fundamental demand despite unfavorable weather conditions in many of its prime crop markets. Extremely wet conditions across the Central and Southern regions of the continental United States delayed corn and cotton planting, shortened the growing season and caused many growers to plant their crops without taking the time to perform various crop protection measures or, alternatively, to forgo corn in favor of planting soybeans which requires a shorter growing period. As a result, AVD's first half performance was characterized by robust first quarter sales on strong demand, and second quarter sales roughly flat with the prior year. This culminated in higher than normal in channel inventories at the end of the planting season. Despite these recent planting difficulties, growers continue to embrace the importance of conventional chemistry solutions for yield enhancement as part of integrated pest management practices.

Half year net sales of our insecticides group were up about 17% to \$118,085 as compared to \$101,266 during the first half of 2012. Within this segment, net sales of our granular soil insecticides ( GSIs ) were up approximately 28% over that of the comparable period in 2012. Our premier corn soil insecticide Aztec increased nearly 93% and our SmartChoice product tripled in sales to lead this surge. Thimet sales declined due to decreased peanut acres being planted in 2013. Net sales of our non-GSI insecticides were approximately 36% lower during the first half of 2013 as compared to the same period of the prior year, largely because sales of our foliar cotton insecticide Bidrin were reduced due to lower cotton plantings.

**Table of Contents**

Within the group of herbicides/fungicides/fumigants, net sales for the first half of 2013 were 73% higher as compared to the first half of 2012. Net sales of our herbicide products tripled, led by our post-emergent corn herbicide Impact. AVD continues to benefit from the co-marketing program with Monsanto's Roundup herbicide brands and from increased supply availability. Partially offsetting this gain, we experienced a modest decline in net sales of our herbicide Dacthal<sup>®</sup> used in high value vegetable crop applications and a slight sales decline for our soil fumigants in the first half of 2013, as compared to the same period of the prior year.

Within the group of other products (which includes plant growth regulators, molluscicides and tolling activity), our net sales dropped by about 18% as compared to those in the first half of 2012. Contributing to this decrease were lower sales of our cotton harvest aid, Folex, due to a drop in cotton acres planted and declines in toll manufacturing revenues and pharmaceutical sales.

Our non-crop sales for the first half of 2012 were \$15,609 as compared to \$16,911 for the same period of the prior year. Sales of our mosquito adulticide Dibrom<sup>®</sup>, were essentially flat, while we saw a decline in net sales of our Pest Strip business driven by timing of customer orders.

Our cost of sales for first six months of 2013 was \$112,451 or 54% of net sales. This compared to \$96,368 or 56% of net sales for 2012. The Company aggregates a number of key variable, semi-variable and fixed cost components within reported cost of sales. The two major components are raw materials (including sub contract costs) and factory operating costs. As a result of significantly higher sales volumes and a different mix of products sold, our absolute total cost of raw materials increased by approximately 14%, driven by sales up 21%. Within this increased cost, our actual purchasing costs for raw materials increased by 1.1%. During 2013 the Company continued to focus on selling higher margin and higher cost products and de-emphasized lower margin, lower cost products facing generic competition. Our factory operating costs (which include fixed and semi-variable costs) increased by 28%, supporting the forecast increase in sales revenue referenced and approximately a 3% increase in inflation. The changes in selling price, volume, product mix and cost of sales resulted overall in a 2% improvement in gross margin to 46% in 2013 as compared to 44% for the same period of the prior year.

It should be noted that, when making comparisons with other companies' financial statements, the Company reports distribution costs in operating expenses and not as part of cost of sales.

Operating expenses increased by \$9,718 to \$56,798 for the six months ended June 30, 2013, as compared to the same period in 2012. The differences in operating expenses by department are as follows:

|  | 2013      | 2012      | Change   |
|--|-----------|-----------|----------|
| Selling                                      | \$ 15,682 | \$ 12,115 | \$ 3,567 |
| General and administrative                   | 20,171    | 13,828    | 6,343    |
| Research, product development and regulatory | 9,612     | 10,472    | (860)    |
| Freight, delivery and warehousing            | 11,333    | 10,665    | 668      |
|  | \$ 56,798 | \$ 47,080 | \$ 9,718 |

Selling expenses for the period increased by about 29% over the comparable period. This increase is driven by higher costs associated with advertising and promotions, field stewardship costs and an expanded sales force.

General and administrative expenses increased by about 46% over the same period of 2012. The main drivers are the increased size and cost of our support organization, higher incentive compensation as a result of our business performance, and additional legal costs on a data compensation matter that concluded in July 2013.

Research, product development costs and regulatory expenses decreased by about 8% when compared to the same period of 2012. This is as a result of timing and mix of external regulatory studies.

## Edgar Filing: AMERICAN VANGUARD CORP - Form 10-Q

Freight, delivery and warehousing costs for the six months ended June 30, 2013 were \$11,333 or 5.4% of sales as compared to \$10,665 or 6.2% of sales for the same period in 2012. This reflects sales which were up 21% including significantly higher sales of our Impact product which, because of packaging and concentration, has lower freight costs.

**Table of Contents**

Interest costs net of capitalized interest, were \$1,023 in the six months of 2013 as compared to \$1,308 in the same period of 2012. Interest costs are summarized in the following table:

***Average Indebtedness and Interest expense***

|  | Six months ended June 30, 2013 |                  |               | Six months ended June 30, 2012 |                  |               |
|--|--------------------------------|------------------|---------------|--------------------------------|------------------|---------------|
|  | Average Debt                   | Interest Expense | Interest Rate | Average Debt                   | Interest Expense | Interest Rate |
| Term loan                                  | \$ 47,023                      | \$ 880           | 3.7%          | \$ 52,956                      | \$ 973           | 3.7%          |
| Working capital revolver                   | 16,956                         | 189              | 2.2%          |                                |                  |               |
| <b>Average</b>                             | <b>63,979</b>                  | <b>1,069</b>     | <b>3.3%</b>   | <b>52,956</b>                  | <b>973</b>       | <b>3.7%</b>   |
| Other notes payable                        | 327                            | 4                | 2.4%          | 6,453                          | 110              | 3.4%          |
| Interest income                            |                                |                  |               |                                |                  |               |
| Capitalized interest                       |                                | (225)            |               |                                | (148)            |               |
| Amortization of deferred loan fees         |                                | 70               |               |                                | 64               |               |
| Amortization of other deferred liabilities |                                | 86               |               |                                | 284              |               |
| Other interest expense                     |                                | 19               |               |                                | 25               |               |
| <b>Adjusted average indebtedness</b>       | <b>\$ 64,306</b>               | <b>\$ 1,023</b>  | <b>3.2%</b>   | <b>\$ 59,409</b>               | <b>\$ 1,308</b>  | <b>4.4%</b>   |

The Company's average overall debt for the six months ended June 30, 2013 was \$64,306 as compared to \$59,409 for the same period of 2012. Furthermore, during the six months to June 30, 2013, we incurred non-cash costs related to amortization of discounting of deferred payments and other interest income in the amount of \$46 as compared to interest expense of \$335 for the same period of the prior year. As can be seen from the table above, the effective rate on our bank borrowings was 3.3% for the period to June 30, 2013 as compared to 3.7% for the same period of the prior year. Our overall effective interest rate was 3.2% for the six months ended June 30, 2013 as compared to 4.4% in the same period of 2012.

During the three months ended June 30, 2013, the Company borrowed under its revolving credit line to fund working capital needs (principally inventory) until the main accounts receivable payments became due on June 15, 2013. During the period beginning on April 15 and ending on June 7 2013, the Company borrowed up to \$53,000 before paying the revolving credit line down following receiving payments from customers on accounts receivable.

Income tax expense has increased by \$3,083 to end at \$12,941 for the six months ended June 30, 2013 as compared to \$9,858 for the comparable period in 2012. The effective tax rate for the six months is 34.03% as compared to 36.06% in the same period of the prior year. The reduction in the rate is primarily driven by the increased benefit from domestic production activities, Alabama income tax capital credit, and higher foreign income.

Our overall net income attributed to American Vanguard for the six months of 2013 was \$25,301 or \$0.88 per share (diluted) as compared to \$17,478 or \$0.61 per share (diluted) in the same period of 2012.

***LIQUIDITY AND CAPITAL RESOURCES***

The Company generated \$20,045 of cash in operating activities during the six months ended June 30, 2013. This compared to \$36,668 in the same period of last year. Net income of \$25,085, the sum of non-cash depreciation, amortization of intangibles, other assets and discounted future liabilities equaled \$9,349 and stock based compensation expense of \$1,747 provided a net cash inflow \$36,121 compared to \$27,365 for the same period last year.

During the six months ended June 30, 2013, the Company had very strong sales of its key corn products during the first three months, followed by a flattening of sales during the second three-month period. Sales of our Herbicide products have gone well throughout the period. As a result of the strong early sales, our accounts receivable outstanding grew to a very high level in the middle of the period, followed by substantial collections in June (as expected). With slower sales in the final part of the period, we ended with a substantially lower accounts receivable balance of \$67,376 at June 30, 2013. Further, we have been able to reduce our accrual for potential problem accounts to \$557 from \$623 at



Edgar Filing: AMERICAN VANGUARD CORP - Form 10-Q

March 31, 2013.

Inventory levels have increased significantly during the period as a result of the continued adverse weather conditions in our key corn markets. Inventory ended at \$127,150 as compared to \$87,591 at December 31, 2012.

**Table of Contents**

The Company accrues programs in line with the growing season upon which specific products are targeted. Typically crop products have a growing season that ends on September 30 each year. During the six months ended June 30, 2013, the Company made accruals in the amount of \$65,842. Programs are paid out to customers either in the final quarter of the fiscal year or the first quarter of the next fiscal year. During the six months ending June 30, 2013, the Company made payments in the amount of \$8,179. Payments are not generally significant in the second and third quarters of each financial year. During the six months to the end of June 30, 2012, the Company accrued \$37,252 and made payments in the amount of \$4,372.

Finally, as the Company was building momentum for the 2013 growing season, prepaid expenses and other assets increased by \$8,885. At the same time, accounts payable decreased \$8,532.

The Company utilized \$12,047 in investing activities during the six months ended June 30, 2013. This compares to \$13,061 for the same period of the prior year. The business is spending primarily to expand manufacturing capacity in response to demand for certain core products. Furthermore, during the six months ended June 30, 2013, the Company made a \$3,687 equity investment in TyraTech Inc., a natural life science company that utilizes its proprietary technology to develop solutions to address the unmet and increasing global demand for effective, safe, and non-toxic insect and parasite technologies for human and animal health.

Financing activities used \$14,034 during the six months ended June 30, 2013, compared to providing \$10,762 in the same period of the prior year. This included the net debt reduction achieved following the refinancing of our senior credit facility at the end of June 2013 and deferred payments on notes related to product acquisitions. The Company made dividend payments in the amount of \$1,976 as compared to \$1,380 in the same period of last year. Finally, the Company received \$527 from the exercise of stock options and the sale of common stock under its Employee Stock Purchase Plan (including associated tax benefits) as compared to \$1,285 for the same period last year.

The Company has various different loans in place that together constitute the short-term and long-term loan balances shown in the balance sheet at June 30, 2013 and December 31, 2012. These are summarized in the following table:

| Indebtedness<br>\$000 s                                  | June 30, 2013 |            |           | December 31, 2012 |            |           |
|--|---------------|------------|-----------|-------------------|------------|-----------|
|  | Long-term     | Short-term | Total     | Long-term         | Short-term | Total     |
| Term Loan  | \$            | \$         | \$        | \$ 36,000         | \$ 10,000  | \$ 46,000 |
| Working capital revolver                                 | 40,750        |            | 40,750    |                   |            |           |
| Notes payable on product acquisitions and asset purchase | 161           | 70         | 231       | 196               | 6,247      | 6,443     |
| Total Indebtedness                                       | \$ 40,911     | \$ 70      | \$ 40,981 | \$ 36,196         | \$ 16,247  | \$ 52,443 |

As more fully reported in the Company's Form 8-K (filed with the SEC on June 20, 2013), on June 17, 2013, AMVAC Chemical Corporation (AMVAC), the Company's principal operating subsidiary, as borrower, and affiliates (including the Company), as guarantors and/or borrowers, entered into a Second Amended and Restated Credit Agreement (the New Credit Agreement) with a group of commercial lenders led by Bank of the West (AMVAC's primary bank) as agent, swing line lender and L/C issuer. The new facility also includes both AMVAC CV and AMVAC Netherlands BV (both Dutch subsidiaries) as borrowers. The New Credit Agreement supersedes the Amended and Restated Credit Agreement (First Amendment) dated as of January 10, 2011 and more fully described in the Company's Form 8-K filed on January 13, 2011. The New Credit Agreement is a senior secured lending facility with a five year term and consists of a revolving line of credit of \$200 million and an accordion feature for up to \$100 million. In connection with AMVAC's entering into the New Credit Agreement, all outstanding indebtedness under the First Amendment was rolled over into the New Credit Agreement, and term loans were converted into revolving debt.

The Company has three key covenants under the New Credit Agreement (with which AMVAC is in compliance). The covenants are as follows: The Company must (1) maintain its borrowings below a certain consolidated funded debt ratio, (2) limit its annual spending on the acquisition of fixed asset capital additions, and (3) maintain a certain consolidated fixed charge coverage ratio.

At June 30, 2013, based on its performance against the most restrictive covenants listed above, the Company had the capacity to increase its borrowings by up to \$159,250 under the credit facility agreement.

**Table of Contents****RECENTLY ISSUED ACCOUNTING GUIDANCE**

In February 2013, The Financial Accounting Standards Board ( FASB ) issued Accounting Standards Update ( ASU ) 2013-02, *Comprehensive Income (Topic 220): Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income*, which establishes new requirements for disclosing reclassifications of items out of accumulated other comprehensive income (OCI). Specifically, (1) disclosure is required of the changes in components of accumulated OCI, (2) disclosure is required of the effects on individual line items in net income for each item of accumulated OCI that is reclassified in its entirety to net income, and (3) cross references are required to other disclosures that provide additional details for OCI items that are not reclassified in their entirety to net income. The requirements of ASU 2013-02 apply to all entities (i.e., both public and nonpublic) that report items of OCI in any period presented. ASU 2013-02 is effective prospectively for reporting periods beginning after December 15, 2012.

In October 2012, FASB issued ASU No. 2012-04, Technical Corrections and Improvements. This update primarily makes amendments to various Codifications to (1) conform the format and writing style of certain guidance carried forward without modification from pre-Codification pronouncements, (2) to correct references and provide clarification through updated language, and (3) to relocate guidance within the Codification to a more appropriate location. In addition, ASU No. 2012-4 conforms the use of the term *fair value* throughout the Codification to reflect fully the measurement and disclosure requirements of FASB ASC Topic 820, *Fair Value Measurement and Disclosures* (e.g. to replace the terms market value and mark-to-market with fair value and subsequently measure at fair value, respectively). The majority of the amendments do not change the accounting practice. However, where applicable, the Company will apply the updates.

**CRITICAL ACCOUNTING POLICIES AND ESTIMATES**

The Company continually re-assesses the critical accounting policies used in preparing its financial statements for inclusion in the American Vanguard published financial statements. In the Company's statement 10-K for the financial year ended December 31, 2012, the Company provided a comprehensive statement of critical accounting policies. These policies have been reviewed in detail as part of the preparation work for this 10-Q statement. All the policies listed in the Company's Form 10-K for the year ended December 31, 2012 remain valid and is hereby incorporated by reference.

**Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK**

The Company is exposed to market risk related to changes in interest rates, primarily from its borrowing activities. The Company's indebtedness to its primary lender is evidenced by a line of credit with a variable rate of interest, which fluctuates with changes in the lender's reference rate. For more information, please refer to the applicable disclosures in the Company's Form 10-K filed with the SEC for the year ended December 31, 2012. The Company uses derivative financial instruments for trading purposes to protect trading performance from exchange rate fluctuations on material contracts; also, as a condition of the Company's credit agreement with its banks, the Company is required to maintain in effect interest rate swap agreement(s) for a notional amount not less than one-half of the principal amount of its term loan.

The Company conducts business in various foreign currencies, primarily in Europe, Mexico, Central and South America. Therefore changes in the value of the currencies of such countries or regions affect the Company's financial position and cash flows when translated into U.S. Dollars. The Company has mitigated and will continue to mitigate a portion of its currency exchange exposure through natural hedges based on the operation of decentralized foreign operating companies in which the majority of all costs are local-currency based. Furthermore, the Company has established a procedure for covering forward exchange rates on specific purchase orders when appropriate. A 10% change in the value of all foreign currencies would have an immaterial effect on the Company's financial position and cash flows.

**Item 4. CONTROLS AND PROCEDURES**

As of June 30, 2013, the Company has established a comprehensive set of disclosure controls and procedures designed to ensure that all information required to be disclosed in our filings under the Securities Exchange Act (1934) is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms. As at June 30, 2013, the Company's management, including the Company's Chief Executive Officer and Chief Financial Officer, has concluded, based on their evaluation, that the Company's disclosure controls and procedures are effective to provide reasonable assurance of the achievement of the objectives described above.

There were no changes in the Company's internal controls over financial reporting that occurred during the most recent quarter that have materially affected, or are reasonably likely to materially affect, the Company's internal controls over financial reporting.



---

**Table of Contents**

**PART II. OTHER INFORMATION**

The Company was not required to report any matters or changes for any items of Part II except as disclosed below.

**Item 1. Legal Proceedings**

Legal Proceedings Summarized below are litigation matters in which there has been material activity or developments since the filing of the Company's Form 10-Q for the period ended March 31, 2013.

**A. DBCP Cases Delaware**

On or about July 21, 2011, an action captioned, *Blanco v. AMVAC Chemical Corporation et al.*, was filed with the Superior Court of the State of Delaware in and for New Castle County (No. N11C-07-149 JOH) on behalf of an individual plaintiff, residing in Costa Rica, against several defendants, including, among others, AMVAC, The Dow Chemical Company, Occidental Chemical Corporation, and Dole Food Company. In the action, plaintiff claims personal injury (sterility) arising from the alleged exposure to DBCP between 1979 and 1980 while working as a contract laborer in a banana plantation in Costa Rica. Defendant Dow filed a motion to dismiss the action as being barred under the applicable statute of limitations, as this same plaintiff filed the same claim in Florida in 1995 and subsequently withdrew the matter. Plaintiff contends that the statute of limitations was tolled by a prior motion for class certification, which was denied. AMVAC contends that the plaintiff could not have been exposed to any DBCP supplied by AMVAC in Costa Rica. On August 8, 2012, the court denied Dow's motion to dismiss based upon applicable statutes of limitation. In response to that denial, on August 20, 2012, defendants filed a motion for interlocutory appeal and, on September 18, 2012, the Delaware Supreme Court granted interlocutory appeal on the question of whether the State of Delaware will recognize cross jurisdictional tolling (that is, whether it is proper for a Delaware court to follow the class action tolling of another jurisdiction, in this case, Texas, rather than its own two year statute of limitations). Pending the ruling on appeal, the *Blanco* matter was stayed. A similar case (referred to as *Chaverri* in the Company's Form 10-K for the period ended December 31, 2012) involving claims for personal injury allegedly arising from exposure to DBCP on behalf of 235 banana workers from Costa Rica, Ecuador and Panama was also stayed pending the ruling. The Delaware Supreme Court heard oral argument on April 10, 2013 and, on June 10, 2013, denied the appeal and upheld the lower court ruling in *Blanco*, holding that it was proper to extend the class action tolling exception to cross-jurisdictional class action cases. With that ruling, both the *Blanco* and *Chaverri* matters remain pending. AMVAC intends to defend both of these matters vigorously and, at this early stage of litigation, does not believe that a loss is either probable or reasonably estimable and has not set up a loss contingency for either matter.

The balance sheet at June 30, 2013 includes loss contingencies relating to certain legal proceedings more fully described in Item 3 of the Company's Form 10-K for the period ended December 31, 2012 (the 2012 10-K). To the extent that there has been no material change in any such proceeding or in the contingency related thereto since the filing of the 2012 10-K, no additional disclosure about such matter is included in this Form 10-Q.

**Item 1A. Risk Factors**

The Company continually re-assesses the business risks, and as part of that process detailed a range of risk factors in the disclosures in American Vanguard's Report on Form 10-K for the fiscal year ended December 31, 2012, filed on March 1, 2013. In preparing this document, we have reviewed all the risk factors included in that document and find that there are no material changes to those risk factors.

**Table of Contents**

**Item 6. Exhibits**

**Exhibits required to be filed by Item 601 of Regulation S-K:**

**Exhibit**

| <b>No.</b> | <b>Description</b>   |
|------------|--|
| 31.1       | Certification of Chief Executive Officer Pursuant to Section 302 of The Sarbanes-Oxley Act of 2002.  |
| 31.2       | Certification of Chief Financial Officer Pursuant to Section 302 of The Sarbanes-Oxley Act of 2002.  |
| 32.1       | Certification Pursuant to Section 906 of The Sarbanes-Oxley Act of 2002.   |
| 101        | The following materials from American Vanguard Corp s Quarterly Report on Form 10-Q for the quarter ended June 30, 2013, formatted in XBRL (Extensible Business Reporting Language): (i) Condensed Consolidated Balance Sheet; (ii) Condensed Consolidated Statements of Income; (iii) Condensed Consolidated Statements of Cash Flows; (iv) Condensed Consolidated Statements of Shareholders Equity; and (v) Notes to Condensed Consolidated Financial Statements, tagged as blocks of text. |

**Table of Contents**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

AMERICAN VANGUARD CORPORATION

Dated: August 5, 2013

By: */s/* ERIC G. WINTEMUTE  
**Eric G. Wintemute**

**Chief Executive Officer and Chairman of the Board**

Dated: August 5, 2013

By: */s/* DAVID T. JOHNSON  
**David T. Johnson**

**Chief Financial Officer & Principal Accounting Officer**